Annexin V and anti-Annexin V antibodies: two interesting aspects in acute myocardial infarction
- PDF / 238,349 Bytes
- 6 Pages / 610 x 792 pts Page_size
- 95 Downloads / 141 Views
BioMed Central
Open Access
Original basic research
Annexin V and anti-Annexin V antibodies: two interesting aspects in acute myocardial infarction Mohammad Shojaie*1, Abdoreza Sotoodah2, Shohre Roozmeh3, Ensieh Kholoosi3 and Samira Dana3 Address: 1Department of Cardiology, Jahrom University of Medical science, Jahrom, Iran, 2Department of Immunology, Jahrom University of Medical science, Jahrom, Iran and 3Department of Medicine, Jahrom University of Medical science, Jahrom, Iran Email: Mohammad Shojaie* - [email protected]; Abdoreza Sotoodah - [email protected]; Shohre Roozmeh - [email protected]; Ensieh Kholoosi - [email protected]; Samira Dana - [email protected] * Corresponding author
Published: 21 July 2009 Thrombosis Journal 2009, 7:13
doi:10.1186/1477-9560-7-13
Received: 22 February 2009 Accepted: 21 July 2009
This article is available from: http://www.thrombosisjournal.com/content/7/1/13 © 2009 Shojaie et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract Background: Myocardial infarction is the combined result of environmental factors and personal predispositions. Prothrombotic factors might play an important role in this phenomenon. Annexin V (ANV) is a calcium-dependent glycoprotein widely present in various tissues exerting a potent anticoagulant effect in vitro by reducing plaque adhesion and aggregation. Anti-annexin V antibodies (aANVAs) are detected in various diseases like rheumatoid arthritis, systemic lupus erythematosus and anti-phospholipid antibody syndrome. The study of ANV in Acute Myocardial Infarction (AMI) might shed light on hypercoagulability mechanisms in the pathogenesis of acute coronary syndromes. This study was conducted to investigate the association of plasma ANV, aANVAs and anti-cardiolipin antibodies (aCLAs) with AMI. Methods: This study recruited 45 patients with the diagnosis of AMI according to WHO criteria in their first 24 hours of admission. 36 matched individuals were studied as the control group with normal coronary artery angiography. Plasma levels of ANV, aANVAs and aCLAs were determined by enzyme-linked immunosorbent assay and the results were compared. Results: Plasma ANV levels in the patients with AMI on admission were significantly lower than those in the control group (p = 0.002). Positive test for aANVAs were found to be present in a significant number of our patients (p = 0.004). The studied groups were similar in their rate of patients with positive aCLAs tests. ANV, aANVAs and aCLAs were not correlated with hypertension, diabetes mellitus, hyperlipidemia, sex, age and smoking. Conclusion: Our findings suggest that low plasma ANV levels along with positive aANVAs tests in patients with AMI are indicative of hypercoagulable state that is not related to the tradition
Data Loading...
